Correlation of E-cadherin protein expression and the risk of pancreatic cancer: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LI Yue ¹ , LI Rui ² , TIAN Wenguang ³ ,  HE Ping ¹

1. Department of Gastroenterology, Yongchuan Hospital of Chongqing Medical University, Yongchuan, 402160, P.R.China;
2. Department of Oncology, Yongchuan Hospital of Chongqing Medical University, Yongchuan, 402160, P.R.China;
3. Department of Infectious Diseases, Yongchuan Hospital of Chongqing Medical University, Yongchuan, 402160, P.R.China;

Corresponding author：

HE Ping, Email: hp661210@163.com

Keywords：

Pancreatic cancer; E-cadherin; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.201612091

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo systematically review the expression of E-cadherin protein and the risk of pancreatic cancer. MethodsWe searched PubMed, EMbase, The Cochrane Library, CNKI, VIP, CBM and WanFang Data from inception to October 2016 to collect case-control studies about the correlation between E-cadherin protein expression and the risk of pancreatic cancer. Two reviewers independently screened the literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed using RevMan 5.2 software and Stata 12.0 software. ResultsSeventeen studies (986 cases in pancreatic cancer group and 433 cases in normal pancreatic tissue group) were finally included. The results of meta-analysis showed that: the expression of E-cadherin protein in the pancreatic cancer group was lower than normal tissue group (OR=0.04, 95%CI 0.01 to 0.23, P=0.000 2), poor differentiation group was lower than high or middle differentiation group (OR=0.44, 95%CI 0.26 to 0.76, P=0.003), lymph node metastasis group was lower than without lymph node metastasis group (OR=0.50, 95% CI 0.31 to 0.81, P=0.005), and the difference was statistically significant. However, there was no significant difference between the clinical stageⅠ-Ⅱ group and Ⅲ-Ⅳ group (OR=0.63, 95%CI 0.25 to 1.59, P=0.33), pancreatic head cancer group and pancreatic body and tail cancer group (OR=1.22, 95%CI 0.72 to 2.07, P=0.46), pancreatic cancer with nerve invasion group and without nerve invasion group (OR=1.45, 95%CI 0.81 to 2.62, P=0.21), pancreatic cancer with vascular invasion group and without vascular invasion group (OR=0.55, 95%CI 0.13 to 2.22, P=0.40). ConclusionLower expression of E-cadherin protein is significantly associated with the risk of pancreatic cancer. Due to the limited quality and quanity of includied studies, the above conclusion should be approved by more studies.

Citation： LI Yue, LI Rui, TIAN Wenguang, HE Ping. Correlation of E-cadherin protein expression and the risk of pancreatic cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(7): 760-767. doi: 10.7507/1672-2531.201612091 Copy

1.	Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2013. J Cancer Res Clin, 2013, 63(1): 11-30.
2.	American Cancer Society. Cancer facts and figures 2015. USA: American Cancer Society(ACS): Atlanta, 2015．.
3.	Bhatt T, Rizvi A, Batta SP, et al. Signaling and mechanical roles of E-cadherin. Cell Commun Adhes, 2013, 20(6): 189-199.
4.	Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A, 2014, 111(3): 1090-1095.
5.	Zhou Y, Ming J, Xu Y, et al. ERβ1 inhibits the migration and invasion of breast cancer cells through upregulation of E-cadherin in a Id1-dependent manner. Biochem Biophys Res Commun, 2015, 457(2): 141-147.
6.	Tang W, Zhu Y, Gao J, et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br J Cancer, 2014, 110(2): 450-458.
7.	Wells G, Shea B, O'Connell D, et al. Newcastle-Ottawa Quality Assessment Scale-Case Control Studies. Available at: http://www.oori.ca/programs/clinical-epidemiology/oxford-asp.
8.	费阳, 刘绪舜, 王峰, 等. E-cadherin 在胰腺癌中的表达及与血管生成的关系. 重庆医科大学学报, 2010, 35(10): 1502-1505.
9.	赵海涛, 张海涛. E-cadherin, β-catenin 表达与胰腺癌预后的关系. 实用癌症杂志, 2016, 31(6): 899-904.
10.	冯延平, 黄涛, 高军, 等. EphA2 与 Ecadherin 在胰腺癌中的表达及其意义. 中国普通外科杂志, 2015, 14(12): 914-917.
11.	朱光辉, 岑刚, 黄陈, 等. HIF-1α 和 EMT 相关蛋白在胰腺癌组织中的表达及临床意义. 世界华人消化杂志, 2011, 19(19): 2022-2030.
12.	陈盛, 孟勇, 谢造贤, 等. KLK7 及 E-cadherin 在胰腺癌组织中的表达及其临床意义. 现代医院, 2013, 13(5): 7-9.
13.	蔡重阳, 汤志刚, 黄强, 等. Peroxiredoxin 1 与 EMT 相关蛋白在胰腺癌组织中的表达及其临床意义. 安徽医科大学学报, 2015, 50(3): 368-371.
14.	田峰, 方瑞忠, 徐建. 基质金属蛋白酶-2 和 E-钙黏蛋白在胰腺癌组织中的表达及临床意义. 中国现代医学杂志, 2016, 26(9): 34-38.
15.	刘宇, 刘建生. 角质细胞生长因子及 E-钙黏蛋白在胰腺癌组织中的表达及其意义. 肿瘤研究与临床, 2008, 20(4): 247-249.
16.	黄项武, 程志清, 林芳英, 等. 胰腺癌中 MMP-9 和 E-cad 的表达及意义. 中国实用医药, 2011, 6(32): 28-30.
17.	刘晓飞, 李宜雄. 胰腺癌组织 Syndecan-1 和 E-cadherin 表达临床意义的研究. 中华肿瘤防治杂志, 2009, 16(9): 680-693.
18.	马广念. Dysadherin、E-Cadherin 在胰腺癌组织中的表达及临床意义研究. 湛江: 广东医学院, 2009.
19.	赵军, 姚建峰, 马建仓, 等. E-钙粘蛋白及增殖细胞核抗原在胰腺癌组织中的表达及意义.西安交通大学学报, 2006, 27(3): 267-270.
20.	周晓晖. 胰腺癌预后因素分析和 EMT 的作用研究. 上海: 复旦大学, 2007.
21.	刘洪锋. S100A4、MMP-2 和 E-cad 在胰腺癌组织中的表达及意义. 郑州: 郑州大学, 2011.
22.	Shin SJ, Kim KO, Kim MK, et al. Expression of E-Cadherin and uPA and their association with the prognosis of pancreatic cancer.Jpn J Clin Oncol, 2005, 35(6): 342-348.
23.	Guo S, Xu JJ, Xue R, et al. Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol, 2013, 19(2): 319-324.
24.	Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroentero, 2003, 9(2): 368-372.
25.	Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999, 24: 73-76.
26.	Nigam AK, Savage FJ, Boulos PB, et al. Loss of cell–cell and cell-matrix adhesion molecules in colorectal cancer. Br J Cancer. 1993, 68(3): 507-514.
27.	Wang ZS, Shen Y, Li X, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric Cancer. Tumour Biol, 2014, 35(2): 1357-1363.
28.	Hashiguchi M, Ueno S, Sakoda M, et al. Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma(HCC). BMC Cancer, 2013, 13(1): 572.
29.	Rodilla I, Aller L, Llorca J, et al. The E-Cadherin expression Vs. Tumor cell proliferation paradox in endometrial cancer. Anticancer Res, 2013, 33(11): 5091-5095.
30.	Zheng X, Du XL, Jiang T. Prognostic significance of reduced immunohistochemical expression of E-cadherin in endometrial cancer-results of a meta-analysis. Int J Clin Exp Med, 2015, 8(10): 18689-18696．.

1. Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2013. J Cancer Res Clin, 2013, 63(1): 11-30.
2. American Cancer Society. Cancer facts and figures 2015. USA: American Cancer Society(ACS): Atlanta, 2015．.
3. Bhatt T, Rizvi A, Batta SP, et al. Signaling and mechanical roles of E-cadherin. Cell Commun Adhes, 2013, 20(6): 189-199.
4. Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A, 2014, 111(3): 1090-1095.
5. Zhou Y, Ming J, Xu Y, et al. ERβ1 inhibits the migration and invasion of breast cancer cells through upregulation of E-cadherin in a Id1-dependent manner. Biochem Biophys Res Commun, 2015, 457(2): 141-147.
6. Tang W, Zhu Y, Gao J, et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br J Cancer, 2014, 110(2): 450-458.
7. Wells G, Shea B, O'Connell D, et al. Newcastle-Ottawa Quality Assessment Scale-Case Control Studies. Available at: http://www.oori.ca/programs/clinical-epidemiology/oxford-asp.
8. 费阳, 刘绪舜, 王峰, 等. E-cadherin 在胰腺癌中的表达及与血管生成的关系. 重庆医科大学学报, 2010, 35(10): 1502-1505.
9. 赵海涛, 张海涛. E-cadherin, β-catenin 表达与胰腺癌预后的关系. 实用癌症杂志, 2016, 31(6): 899-904.
10. 冯延平, 黄涛, 高军, 等. EphA2 与 Ecadherin 在胰腺癌中的表达及其意义. 中国普通外科杂志, 2015, 14(12): 914-917.
11. 朱光辉, 岑刚, 黄陈, 等. HIF-1α 和 EMT 相关蛋白在胰腺癌组织中的表达及临床意义. 世界华人消化杂志, 2011, 19(19): 2022-2030.
12. 陈盛, 孟勇, 谢造贤, 等. KLK7 及 E-cadherin 在胰腺癌组织中的表达及其临床意义. 现代医院, 2013, 13(5): 7-9.
13. 蔡重阳, 汤志刚, 黄强, 等. Peroxiredoxin 1 与 EMT 相关蛋白在胰腺癌组织中的表达及其临床意义. 安徽医科大学学报, 2015, 50(3): 368-371.
14. 田峰, 方瑞忠, 徐建. 基质金属蛋白酶-2 和 E-钙黏蛋白在胰腺癌组织中的表达及临床意义. 中国现代医学杂志, 2016, 26(9): 34-38.
15. 刘宇, 刘建生. 角质细胞生长因子及 E-钙黏蛋白在胰腺癌组织中的表达及其意义. 肿瘤研究与临床, 2008, 20(4): 247-249.
16. 黄项武, 程志清, 林芳英, 等. 胰腺癌中 MMP-9 和 E-cad 的表达及意义. 中国实用医药, 2011, 6(32): 28-30.
17. 刘晓飞, 李宜雄. 胰腺癌组织 Syndecan-1 和 E-cadherin 表达临床意义的研究. 中华肿瘤防治杂志, 2009, 16(9): 680-693.
18. 马广念. Dysadherin、E-Cadherin 在胰腺癌组织中的表达及临床意义研究. 湛江: 广东医学院, 2009.
19. 赵军, 姚建峰, 马建仓, 等. E-钙粘蛋白及增殖细胞核抗原在胰腺癌组织中的表达及意义.西安交通大学学报, 2006, 27(3): 267-270.
20. 周晓晖. 胰腺癌预后因素分析和 EMT 的作用研究. 上海: 复旦大学, 2007.
21. 刘洪锋. S100A4、MMP-2 和 E-cad 在胰腺癌组织中的表达及意义. 郑州: 郑州大学, 2011.
22. Shin SJ, Kim KO, Kim MK, et al. Expression of E-Cadherin and uPA and their association with the prognosis of pancreatic cancer.Jpn J Clin Oncol, 2005, 35(6): 342-348.
23. Guo S, Xu JJ, Xue R, et al. Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol, 2013, 19(2): 319-324.
24. Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroentero, 2003, 9(2): 368-372.
25. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999, 24: 73-76.
26. Nigam AK, Savage FJ, Boulos PB, et al. Loss of cell–cell and cell-matrix adhesion molecules in colorectal cancer. Br J Cancer. 1993, 68(3): 507-514.
27. Wang ZS, Shen Y, Li X, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric Cancer. Tumour Biol, 2014, 35(2): 1357-1363.
28. Hashiguchi M, Ueno S, Sakoda M, et al. Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma(HCC). BMC Cancer, 2013, 13(1): 572.
29. Rodilla I, Aller L, Llorca J, et al. The E-Cadherin expression Vs. Tumor cell proliferation paradox in endometrial cancer. Anticancer Res, 2013, 33(11): 5091-5095.
30. Zheng X, Du XL, Jiang T. Prognostic significance of reduced immunohistochemical expression of E-cadherin in endometrial cancer-results of a meta-analysis. Int J Clin Exp Med, 2015, 8(10): 18689-18696．.

Chinese Journal of Evidence-Based Medicine

Correlation of E-cadherin protein expression and the risk of pancreatic cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content